AOD-9604 (5 mg Vial) Dosage Protocol

Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).

• Peptide Vials (AOD-9604, 5 mg each):
  • 8 weeks: approximately 5 vials required
  • 12 weeks: approximately 8 vials required
  • 16 weeks: approximately 11 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (5 vials): 15 mL — 2 bottles required (10 mL each)
  • 12 weeks (8 vials): 24 mL — 3 bottles required (10 mL each)
  • 16 weeks (11 vials): 33 mL — 4 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

AOD-9604 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.667 mg/mL (1667 mcg/mL) concentration.
• Typical daily range: 300–500 mcg once daily (gradual titration).
• Easy measuring: At 1.667 mg/mL, 1 unit = 0.01 mL ≈ 16.67 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

AOD-9604 is a synthetic 16-amino-acid fragment derived from the C-terminal region of human growth hormone. Published human research primarily evaluated oral or intravenous administration, while FDA materials identify no human information for proposed subcutaneous use. The table below retains the page’s existing schedule and focuses on strength-specific concentration, volume, U-100 markings, vial yield, and supplies.^[1][3]

AOD-9604 is a synthetic peptide consisting of a 16-amino acid sequence derived from the C-terminal region of human growth hormone. It is a peptide fragment of human growth hormone, not full-length HGH. It was developed as an investigational compound for metabolic and obesity research, but AOD-9604 is not FDA-approved. FDA’s current review identifies limited route-specific safety information, unresolved peptide-characterization questions, and potential immunogenicity concerns for compounded AOD-9604.^[1][2]

• Vial-specific math: A 5 mg vial prepared to 3.0 mL contains approximately 1.667 mg/mL, or 1,667 mcg/mL.
• U-100 conversion: One unit is 0.01 mL and contains approximately 16.67 mcg at this concentration.
• Displayed schedule: The dosage chart above retains this page’s established 300 mcg and 500 mcg calculation rows. It is labeled as community-reported use, not as an FDA-approved regimen or a schedule validated by a subcutaneous human trial.
• Evidence boundary: Published human AOD-9604 studies summarized safety data from oral and intravenous research. They do not establish the subcutaneous schedule displayed on this page.^[3]

The primary table combines peptide mass, U-100 syringe units, liquid volume, frequency, and duration so each row can be interpreted without a second chart. The arithmetic is based on the vial strength and final volume:

5 mg ÷ 3.0 mL = 1.667 mg/mL. Desired amount ÷ 1,667 mcg/mL = injection volume. Injection volume × 100 = U-100 units.

• 300 mcg equals approximately 0.18 mL, or 18 units on a U-100 syringe.
• 500 mcg equals approximately 0.30 mL, or 30 units on a U-100 syringe.
• One U-100 unit is a 0.01 mL volume marking, not a peptide international unit.

An AOD-9604 dosage calculator can reproduce these conversions, but it cannot select a dose, establish suitability, or convert a community-reported schedule into clinical evidence. Changing the vial strength or final volume changes the unit conversion even when the peptide amount is the same.

AOD-9604 is also described in the literature as Tyr-hGH 177-191 or LAT8881. The molecule was designed from the lipolytic region of human growth hormone while researchers investigated whether metabolic effects could be separated from the growth-promoting activity associated with full-length growth hormone.^[3][4]

The name identifies a research peptide, not an approved indication. AOD-9604, human growth hormone, and other growth-hormone fragments should not be treated as interchangeable. Sequence, formulation, route, dose, and exposure all affect how a research finding can be interpreted.

A 2013 publication in the Journal of Endocrinology and Metabolism summarized six randomized, double-blind, placebo-controlled clinical trials involving 893 participants. The early studies used intravenous infusion, while later studies used oral AOD-9604. The publication reported no consistent increase in IGF-1, no adverse effect on oral glucose-tolerance testing, and no detected antibodies against the peptide in the tested participants.^[3]

Those findings require careful qualification. The study authors disclosed financial interests, the work summarized development-program data, and the administration routes do not match the subcutaneous community schedule shown above. FDA’s later review concluded that human safety information remains limited and that it found no human information for proposed subcutaneous and transdermal uses.^[1]

Route matters because oral, intravenous, intra-articular, and subcutaneous administration can produce different exposure, formulation, sterility, and immunogenicity questions. Evidence from one route cannot automatically validate another.

AOD-9604 was investigated for obesity, but the development program did not establish a reliable approved weight-loss therapy. An official clinical-trial protocol for the later LAT8881 program states that phase 2 obesity studies did not show statistically significant weight loss and that development for that indication was discontinued.^[5]

This history is important when interpreting searches for AOD-9604 dosage for weight loss, fat loss peptide dosage, or AOD-9604 results. A calculation table can show how many micrograms are present in a syringe volume, but it cannot establish that the amount produces meaningful fat loss, preserves muscle, targets abdominal fat, or improves metabolic health.

The site therefore separates three different questions: what the vial contains, how the arithmetic converts to U-100 markings, and what published research actually demonstrates. Only the first two are answered directly by the 5 mg vial calculation.

Early rodent research examined whether AOD-9604 could stimulate lipolytic activity in adipose tissue. In obese Zucker rats, researchers reported increased activity without the same insulin-sensitivity effect observed with full-length growth hormone.^[4] A separate mouse study linked chronic AOD-9604 exposure with changes in body weight, fat mass, fat cell sensitivity, and beta-3 adrenergic receptor expression.^[6]

These findings are preclinical. Animal dose, route, metabolism, and experimental conditions cannot be converted directly into a human AOD-9604 dosage protocol. The mouse study also found that the proposed mechanism was more complex than a direct beta-3 receptor effect, so simplified claims that AOD-9604 merely “turns on fat burning” overstate what the research establishes.^[6]

A rabbit osteoarthritis study evaluated intra-articular AOD-9604, with or without hyaluronic acid, in a collagenase-induced knee model. The study reported histologic and functional differences among the animal groups.^[7]

That experiment does not support the subcutaneous dosage chart on this page. It used a different species, disease model, route, formulation context, and research objective. It is included to map the broader evidence base, not to imply a cartilage-repair indication or a dosing recommendation for people.

AOD-9604 is not FDA approved. FDA’s Pharmacy Compounding Advisory Committee materials describe limited clinical safety information, no identified pharmacokinetic or bioavailability information for any route, no human data for proposed subcutaneous use, and unresolved concerns about peptide impurities, aggregation, product characterization, and immunogenicity.^[1]

FDA also lists AOD-9604 among bulk substances that may present significant safety risks in compounding and notes that serious adverse events have been identified, although causality was unclear.^[2] These statements do not mean every research vial has the same risk profile; they mean a product’s identity, purity, sterility, excipients, concentration, storage, and route cannot be inferred from peptide mass alone.

A separate FDA-posted 2021 recall included a compounded injectable AOD-9604 product because sterility assurance was lacking. The recall was product- and lot-specific, but it illustrates why sterile-product quality is a distinct question from dosage arithmetic.^[8]

This AOD-9604 dosage guide separates measurable vial arithmetic from clinical claims. The 5 mg per vial calculation can establish concentration, syringe volume, and vial yield. It cannot establish an ideal AOD-9604 dose, a recommended maximum dosage, or an individualized peptide therapy plan.

Searches for an AOD-9604 peptide dosage, AOD 9604 peptide, or AOD-9604 dosing protocols often combine three different evidence types. This page is a research calculation resource, not a peptide protocol for treatment:

• Published human research: Early clinical studies examined oral and intravenous exposure, not the subcutaneous dosing protocol displayed on this page.^[3]
• Preclinical mechanism research: Animal studies examined body weight, fat-cell activity, fat oxidation, and fat metabolism without establishing a human subcutaneous regimen.^[4][6]
• Community-reported use: The locked 300–500 mcg schedule above is retained as a calculation framework. It should not be presented as a validated standard of care.

This distinction matters because AOD-9604 is not FDA approved, and FDA has not identified human subcutaneous pharmacokinetic, bioavailability, or safety data that would validate the displayed schedule.^[1]

The primary chart preserves this page’s existing 12-week community-reported cycle length and once-daily timing. That continuity keeps the calculation page internally consistent; it does not mean controlled human research has established a best time to take AOD-9604, an optimal cycle length, or a preferred subcutaneous injection schedule.

Human development studies evaluated different routes and protocols, while FDA’s current assessment found no human information for proposed subcutaneous use.^[1][3] For that reason, the schedule is not expanded, shortened, or reinterpreted from search trends. Any future schedule revision would require a separate evidence review and a family-wide protocol decision rather than an SEO edit to one vial strength.

Potential benefits of AOD-9604 have been discussed in relation to body fat reduction, lipid metabolism, and cartilage research, but those topics do not have equal evidentiary support. Preclinical studies reported metabolic or tissue-level findings under controlled animal conditions, whereas the obesity-development program did not produce an approved weight-loss indication.^[4][5][7]

A modified peptide fragment can behave differently from full-length human growth hormone, and a result in one route or species cannot establish safety and tolerability in another. Accordingly, this page does not describe AOD-9604 as a proven fat-loss peptide, does not infer a complete safety profile, and does not convert mechanism research into a dosing recommendation.

The four reconstitution checks above remain the page’s approved 5 mg preparation framework for the peptide vial and bacteriostatic water: add 3.0 mL, direct the liquid slowly down the vial wall, swirl or roll without shaking, then label and refrigerate at 2–8 °C while protecting the vial from light.

• Record the compound name, 5 mg vial strength, 3.0 mL final volume, approximately 1.667 mg/mL concentration, and preparation date.
• Inspect the solution and container against the product’s lot-specific instructions; do not infer identity, sterility, or stability from appearance alone.
• Follow the exact product label and validated documentation for storage, peptide stability, and discard instructions. Do not transfer a use-by period from another peptide, concentration, preservative system, or supplier.
• The linked Pure Lab Peptides record identifies the research vial used for this strength-specific calculation.^[11]

General subcutaneous-injection references describe aseptic preparation, appropriate sites, and systematic site rotation; they do not validate AOD-9604 or the displayed schedule. MedlinePlus advises using a new needle and syringe, cleaning the selected site, and rotating locations to reduce repeated tissue injury.^[9]

• Confirm that the syringe is U-100 before applying the unit conversion on this page.
• Read the liquid level at the leading edge of the plunger and distinguish 18 units from 0.18 mL, and 30 units from 0.30 mL.
• Do not reuse syringes or needles. Place used sharps directly into an appropriate sharps container and follow local disposal requirements.^[10]
• Injection technique information cannot determine whether an investigational substance is appropriate, safe, effective, or permitted.

The World Anti-Doping Agency includes AOD-9604 and hGH 176-191 as examples of prohibited growth-hormone fragments under section S2 of its Prohibited List.^[12] Athletes subject to anti-doping rules should not infer permissibility from a research label, online availability, or the absence of an approved medical indication.

Anti-doping status is separate from safety and efficacy. A prohibited-list entry does not validate a dose, and an educational peptide dosage chart does not provide a therapeutic-use exemption or sport-specific compliance advice.

What is the concentration of a 5 mg AOD-9604 vial mixed with 3 mL?

The concentration is approximately 1.667 mg/mL, or 1,667 mcg/mL. One U-100 unit therefore contains approximately 16.67 mcg.

How many U-100 units equal 300 mcg?

At 1.667 mg/mL, 300 mcg is approximately 0.18 mL, which equals 18 units on a U-100 syringe.

How many U-100 units equal 500 mcg?

At the same concentration, 500 mcg is approximately 0.30 mL, which equals 30 U-100 units.

Is the chart an approved AOD-9604 dosing schedule?

No. The chart retains the site’s established community-reported calculation schedule so the math remains transparent. FDA has not approved AOD-9604, and published human studies do not validate this subcutaneous schedule.^[1][3]

Did human trials prove AOD-9604 causes weight loss?

No approved weight-loss indication resulted from the development program. An official later trial protocol states that phase 2 obesity studies did not show statistically significant weight loss and that development for obesity was discontinued.^[5]

Is AOD-9604 the same as HGH?

No. AOD-9604 is a synthetic peptide fragment derived from a region of human growth hormone. Research findings for one should not be generalized to the other.

Why is this 5 mg page different from the 2 mg page?

The vial strengths produce different concentrations, unit conversions, vial yields, and supply requirements. The 5 mg page targets the broader AOD-9604 dosage topic, while the 2 mg page is reserved for strength-specific calculations and later editorial differentiation.

This page is an educational research reference and does not provide medical advice, diagnosis, treatment, or an individualized dose. The existing 300–500 mcg rows and U-100 markings are retained as a community-reported calculation framework. They are not an FDA-approved regimen, and the academic sources on this page should not be interpreted as validation of subcutaneous AOD-9604 use.

• 1
  U.S. Food and Drug Administration (2024) — Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances.

  View Source
• 2
  U.S. Food and Drug Administration — AOD-9604 entry in the list of bulk substances that may present significant safety risks.

  View Source
• 3
  Journal of Endocrinology and Metabolism (2013) — Safety and tolerability summary of six AOD-9604 human trials.

  View Source
• 4
  Hormone Research (2000) — Metabolic study of AOD-9604 in obese Zucker rats.

  View Source
• 5
  ClinicalTrials.gov — NCT05298306 — Official LAT8881 protocol describing the earlier AOD-9604 obesity-development outcome.

  View Source
• 6
  Endocrinology (2001) — AOD-9604, lipid metabolism, and beta-3 adrenergic-receptor research in obese and knockout mice.

  View Source
• 7
  Annals of Clinical and Laboratory Science (2015) — Intra-articular AOD-9604 research in a rabbit osteoarthritis model.

  View Source
• 8
  U.S. Food and Drug Administration (2021) — Product- and lot-specific recall involving compounded injectable AOD-9604 and sterility assurance.

  View Source
• 9
  MedlinePlus Medical Encyclopedia — General subcutaneous-injection preparation, site, and rotation guidance.

  View Source
• 10
  U.S. Food and Drug Administration — Sharps disposal guidance for used needles and syringes.

  View Source
• 11
  Pure Lab Peptides — AOD-9604 5 mg research-vial supplier record used for the strength-specific calculation.

  View Source
• 12
  World Anti-Doping Agency (2026) — Prohibited List covering growth-hormone fragments, including AOD-9604 and hGH 176-191.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.